newsfilter
← Latest News
GlobeNewswire·

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note